Profile data is unavailable for this security.
About the company
Cyxone AB is a Sweden-based company, which is primarily focused on specialty pharmaceuticals industry. The Company develops cyclotide drugs for autoimmune and other diseases. The Company's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. The product T20K, through a pre-clinical program required for clinical studies in multiple sclerosis. The Company's cyclotides technology can be modified, while keeping the core cyclotide drug structure, to introduce a variety of pharmaceutical properties for selected diseases. The Company has acquired the cyclotide patent rights developed by the Medical University of Vienna and the University Medical Center of Freiburg.
- Revenue in SEK (TTM)0.00
- Net income in SEK-21.66m
- Incorporated2015
- Employees1.00
- LocationCyxone ABAdelgatan 21MALMO 211 22SwedenSWE
- Websitehttps://cyxone.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Redwood Pharma AB | 0.00 | -13.60m | 15.50m | 1.00 | -- | 0.2292 | -- | -- | -5.87 | -5.87 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -106.53 | -95.03 | -121.24 | -123.04 | -- | -- | -- | -- | -- | -19.12 | 0.00 | -- | -- | -- | -8.78 | -- | -5.11 | -- |
| Asarina Pharma AB (publ) | 0.00 | -12.91m | 17.07m | -- | -- | 10.92 | -- | -- | -0.5704 | -0.5704 | 0.00 | 0.069 | 0.00 | -- | -- | -- | -113.04 | -61.28 | -150.47 | -71.81 | -- | -- | -- | -- | -- | -- | 0.3902 | -- | -- | -- | 2.79 | -- | -- | -- |
| Aptahem AB | 32.00k | -11.11m | 17.34m | -- | -- | 0.135 | -- | 541.72 | -0.0497 | -0.0497 | 0.0001 | 0.2266 | 0.0005 | -- | 0.0738 | -- | -16.76 | -39.26 | -19.47 | -44.19 | 4,623.59 | -- | -34,727.72 | -- | -- | -10.17 | 0.0847 | -- | -- | -- | -25.36 | -- | -- | -- |
| Lidds AB | 0.00 | -40.21m | 18.29m | 2.00 | -- | 0.6578 | -- | -- | -0.8316 | -0.8316 | 0.00 | 0.2037 | 0.00 | -- | -- | 0.00 | -184.54 | -46.33 | -274.93 | -51.61 | -- | -1,934.24 | -- | -3,076.68 | -- | -- | 0.00 | -- | -100.00 | -- | -9.08 | -- | -- | -- |
| AegirBio AB | 36.00k | -49.38m | 18.46m | 14.00 | -- | -- | -- | 512.72 | -1.97 | -1.97 | 0.0015 | -0.3413 | 0.0005 | -- | 0.0065 | 2,571.43 | -67.93 | -- | -82.25 | -- | 355.56 | -- | -137,155.60 | -- | 0.5183 | -43.57 | 1.40 | -- | -94.61 | -- | 83.55 | -- | -- | -- |
| Circio Holding ASA | 121.16k | -109.08m | 21.65m | 11.00 | -- | -- | -- | 178.67 | -16.75 | -16.75 | 0.0181 | -12.89 | 0.0019 | -- | 0.0072 | 11,181.82 | -172.29 | -46.58 | -- | -53.40 | -- | -- | -90,029.27 | -6,902.00 | -- | -9.82 | 7.73 | -- | -98.77 | 35.43 | 74.42 | -- | -- | -- |
| Cyxone AB | 0.00 | -21.66m | 27.97m | 1.00 | -- | 0.8183 | -- | -- | -0.1497 | -0.1497 | 0.00 | 0.1589 | 0.00 | -- | -- | -- | -50.57 | -66.19 | -57.08 | -72.35 | -- | -- | -- | -- | -- | -- | 0.0042 | -- | -- | -- | 45.87 | -- | -12.69 | -- |
| Fluicell AB | 1.86m | -29.02m | 33.33m | 12.00 | -- | 1.93 | -- | 17.89 | -0.1936 | -0.1936 | 0.0109 | 0.0527 | 0.0796 | 0.5404 | 1.74 | 109,588.20 | -123.93 | -87.55 | -164.04 | -126.02 | 20.93 | 72.97 | -1,557.49 | -650.23 | 3.02 | -- | 0.00 | -- | 2.68 | 22.18 | -22.90 | -- | -- | -- |
| Gabather AB | 0.00 | -9.44m | 34.37m | -- | -- | 55.01 | -- | -- | -0.652 | -0.652 | 0.00 | 0.0331 | 0.00 | -- | -- | -- | -133.71 | -56.57 | -480.99 | -67.36 | -- | -- | -- | -17,298,800.00 | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- |
| Lipigon Pharmaceuticals AB | 16.41m | -12.13m | 35.40m | -- | -- | 1.24 | -- | 2.16 | -0.4662 | -0.4662 | 0.3201 | 0.225 | 0.7388 | -- | 14.81 | -- | -54.60 | -314.67 | -75.05 | -426.49 | -- | -- | -73.91 | -488.14 | -- | -- | 0.00 | -- | -- | 444.44 | 67.83 | -- | -- | -- |
| Modus Therapeutics Holding AB | 0.00 | -14.96m | 38.45m | 2.00 | -- | 2.64 | -- | -- | -0.7495 | -0.7495 | 0.00 | 0.4056 | 0.00 | -- | -- | 0.00 | -128.10 | -141.06 | -502.76 | -278.44 | -- | -- | -- | -- | -- | -11.79 | 0.00 | -- | -- | -- | 2.31 | -- | -- | -- |
| Elicera Therapeutics AB | 12.85m | -19.50m | 41.41m | 2.00 | -- | 1.31 | -- | 3.22 | -0.9726 | -0.9726 | 0.6416 | 0.901 | 0.3015 | -- | 11.43 | 6,426,955.00 | -45.75 | -40.06 | -62.75 | -49.74 | -- | -- | -151.72 | -415.41 | -- | -- | 0.00 | -- | 777.23 | -- | 15.64 | -- | -- | -- |
